Monte Rosa Therapeutics, Inc.
GLUE
Rank in Stocks
#9138
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to... Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Share Price
$10.58
Last synced: 2026-11-09
Market Cap
$902.62M
Change (1 day)
0.09%
Change (1 year)
-25.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Monte Rosa Therapeutics, Inc. (GLUE)
Category
Healthcare
EPS for Monte Rosa Therapeutics, Inc. (GLUE)
EPS as of September 2026 TTM: $-1.71
According to Monte Rosa Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.71. At the end of 2025 the company had an EPS of $-0.59, an increase over its 2024 EPS of $-0.98.
EPS history for Monte Rosa Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.71 | 189.83% |
| 2025 | $-0.59 | -39.80% |
| 2024 | $-0.98 | -62.74% |
| 2023 | $-2.63 | 14.35% |
| 2022 | $-2.30 | 44.65% |
| 2021 | $-1.59 | 93.90% |
| 2020 | $-0.82 | 355.56% |
| 2019 | $-0.18 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,015.79% |
US
|
|
| $-7.07 | 313.45% |
US
|
|
| $-5.29 | 209.36% |
AU
|
|
| $12.88 | -853.22% |
BE
|
|
| $21.56 | -1,360.82% |
NL
|
Questions about Monte Rosa Therapeutics, Inc.'s earnings per share (EPS)
What is Monte Rosa Therapeutics, Inc.'s earnings per share (EPS)?
Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.71, as of Sep 2026.
What was Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) was $-0.59, compared with $-0.98 in 2024.
How has Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.59) and lowest in 2023 ($-2.63).
How does Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Monte Rosa Therapeutics, Inc.'s earnings per share (EPS) ($-1.71) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.